New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 31, 2014
11:18 EDTACT, ENDPEndo Health wins appeal ruling over Actavis related to Opana ER
A federal appeals court ruled that a district court erred in concluding that Roxane and Actavis (ACT) had an implied license to practice asserted patents related to Opana ER, which is sold in branded form by Endo Health (ENDP). The appeals court vacated the lower court ruling and remanded the suit for further judgment. Reference Link
News For ENDP;ACT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
May 18, 2015
11:21 EDTACTAckman sold out of Actavis stake after Q1 report, NY Post says
Subscribe for More Information
09:20 EDTENDPEndo CEO says will be looking for deals on lower end of $300M-$1B range
Endo will be looking for deals similar to its Aspen transaction, the company's CEO added.
09:09 EDTENDPEndo says 'pretty large' disparity in FY16 interest expense view vs. consensus
Endo said it will not give FY16 guidance at this point but noted that there appears to be a "pretty large" disparity between the company's interest expense view for the fiscal year compared to what appears to be factored into the consensus FY16 forecast. Comments from Endo's call discussing its deal to acquire Par Pharmaceutical.
08:27 EDTENDPEndo says Par financing structure provides flexibility for future M&A
Endo expects adjusted diluted Par EPS to grow faster than revenues, according to slides for the Par Pharmaceutical acquisition presentation. Endo anticipates returns well in excess of its cost of capital, which should enable de-levering to a projected 3-4x net debt to EBITDA in 12-18 months. Endo said the financing structure of the Par deal provides flexibility for future M&A. Endo says consolidation and maturation of competitors have stabilized the generic pharmaceuticals pricing environment and that adding Par creates a top five generics player. Endo said it will have pro forma filed ANDAs of 165 and pro forma programs in development of 152 after adding Par.
08:01 EDTACTActavis launches Namzaric to treat moderate to severe Alzheimer's
Actavis announced that NAMZARIC, a once-daily, fixed-dose combination of memantine hydrochloride extended-release, and donepezil hydrochloride, is now available to patients and healthcare professionals across the United States. NAMZARIC was approved by the FDA in December for the treatment of moderate to severe Alzheimer's disease in patients stabilized on memantine hydrochloride and donepezil hydrochloride.
07:22 EDTACTUBS to hold a conference
Global Healthcare Conference is being held in New York on May 18-20 with webcasted company presentations to begin on May 18 at 8 am; not all company presentations may be webcasted. Webcast Link
07:15 EDTACTPhysician feedback on Actavis Eluxadoline positive, says RBC Capital
After conducting a survey, RBC Capital says that physician enthusiasm about Actavis' Eluxadoline is high ahead of its expected early 2016 launch. The firm thinks the drug could be an important P&L driver for the company and keeps a Top Pick rating on the shares.
06:58 EDTACTActavis CEO says chances of Pfizer offer are 'unlikely', Financial Times says
Actavis (ACT) CEO Brent Saunders said the chances of Pfizer (PFE) making an offer are "incredibly unlikely," reports the Financial Times. Saunders said he has heard the gossip that Actavis could become a takeover target for a larger group, but he spends "zero time thinking about it." Reference Link
06:36 EDTENDPEndo sees PAR transaction accretive to adjusted EPS in first 12 months
Subscribe for More Information
06:34 EDTENDPEndo to acquire Par Pharmaceutical in transaction valued at $8.05B
Endo and Par Pharmaceutical announced that they have entered into a definitive agreement under which Endo will acquire privately-held Par from TPG in a transaction valued at $8.05B, including assumption of Par debt. The combination is expected to help drive long-term double-digit revenue growth for Endo. The transaction has been unanimously approved by the boards of Endo and Par, and is supported by the management teams of both companies. There are no further shareholder approvals required. The purchase price will consist of approximately 18M shares, $1.55B of value based on the 10-day volume weighted average share price of Endo ending on May 15, of Endo equity and $6.50B cash consideration to Par shareholders. Endo has secured fully committed financing from Deutsche Bank and Barclays to fund the cash consideration. Endo expects to implement a permanent capital structure to finance the transaction prior to the close that would include a combination of cash, debt and an equity offering. The transaction is expected to close in the second half of 2015 and is subject to regulatory approval in the U.S. and certain other jurisdictions, as well as other customary closing conditions.
06:33 EDTENDPEndo to acquire Par Pharmaceutical in transaction valued at $8.05B
Subscribe for More Information
06:31 EDTENDPEndo to acquire Par Pharmaceutical in transaction valued at $8.05B
Subscribe for More Information
May 15, 2015
17:40 EDTENDPEndo announces FDA approval of label update for XIAFLEX
Subscribe for More Information
17:15 EDTACTPaulson & Co. gives quarterly update on stakes
Subscribe for More Information
17:08 EDTENDPSoros Fund gives quarterly update on stakes
Subscribe for More Information
17:03 EDTACTPershing Square gives quarterly update on stakes
Subscribe for More Information
14:51 EDTACTMylan ANDA for generic version of Lexapro approved by FDA
The ANDA from Mylan (MYL) for a generic version of Escitalopram Oxalate, which is sold under the trade name Lexapro by Actavis' (ACT) Forest Labs, was approved by the FDA on May 14, according to a post to the regulator's site. Reference Link
12:13 EDTACTThird Point gives quarterly update on stakes
NEW STAKES: Yum! Brands (YUM), NXP Semiconductors (NXPI), FedEx (FDX), McKesson (MCK), and J M Smucker (SJM). INCREASED STAKES: Actavis (ACT), Roper Technologies (ROP), Delta Air Lines (DAL), and FleetCor Technologies (FLT). DECREASED STAKES: Ally Financial (ALLY), Amgen (AMGN), Phillips 66 (PSX), eBay (EBAY), and Anheuser Busch Inbev SA (BUD). LIQUIDATED STAKES: Alibaba Group (BABA), Citigroup (C), EMC Corporation (EMC), Anglo American (AAL), and Williams Companies (WMB).
09:29 EDTACTActavis: Warner Chilcott has held talks with DOJ over sales tactics, WSJ says
Subscribe for More Information
08:30 EDTACTActavis price target raised to $360 from $325 at Susquehanna
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use